Top Page
Microbix Biosystms
(TSX:MBX)
Microbix Biosystms (MBX) vs. iShares MSCI Canada ETF (EWC)
Microbix Biosystms Business Overview & Revenue Model
Microbix Biosystms Earnings Call Summary
Microbix Biosystms Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 18.59M | 18.59M | 25.39M | 16.51M | 19.08M | 18.59M |
| Gross Profit | 9.85M | 9.85M | 15.39M | 7.48M | 11.12M | 11.04M |
| EBITDA | 428.23K | 428.23K | 6.21M | 1.96M | 3.73M | 5.66M |
| Net Income | -2.25M | -2.25M | 3.52M | -39.48K | 1.79M | 1.63M |
Balance Sheet | ||||||
| Total Assets | 37.41M | 37.41M | 38.10M | 35.65M | 33.15M | 28.83M |
| Cash, Cash Equivalents and Short-Term Investments | 12.11M | 12.11M | 12.96M | 11.61M | 13.49M | 9.99M |
| Total Debt | 6.77M | 6.77M | 6.40M | 6.65M | 5.82M | 7.74M |
| Total Liabilities | 9.62M | 9.62M | 9.80M | 11.03M | 8.21M | 10.27M |
| Stockholders Equity | 27.79M | 27.79M | 28.30M | 24.62M | 24.94M | 18.56M |
Cash Flow | ||||||
| Free Cash Flow | -877.58K | -877.58K | 2.44M | -2.11M | 1.44M | 804.20K |
| Operating Cash Flow | -80.29K | -80.29K | 4.35M | -1.09M | 3.47M | 2.11M |
| Investing Cash Flow | -797.30K | -797.30K | -1.91M | -1.02M | -2.03M | -622.34K |
| Financing Cash Flow | 27.00K | 27.00K | -1.08M | 229.21K | 2.06M | 8.41M |
Microbix Biosystms Technical Analysis
Microbix Biosystms Peers Comparison
Microbix Biosystms Corporate Events
Microbix Biosystems Inc., a Canadian life sciences manufacturer specializing in antigens, quality assessment products, and reference materials for the global diagnostics market, has operations spanning over 30 countries and also develops proprietary therapeutics and molecular diagnostic reagents under stringent international regulatory accreditations. The company has updated the investor presentation on its website to add required disclosures explaining its use of EBITDA, after Ontario Securities Commission staff flagged that earlier slides referenced this non-IFRS financial measure without sufficient detail on its composition, usefulness, and reconciliation to IFRS figures; the move reflects an effort to align its continuous disclosure materials more closely with Canadian securities rules and enhance transparency for investors.
The most recent analyst rating on (TSE:MBX) stock is a Hold with a C$0.21 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.
Microbix Biosystems has commercialized its first recombinant antigen product, the SARS-CoV-2 nucleocapsid protein, for use in its QAPs quality assessment line and for sale at commercial scale to test manufacturers, marking the first market-ready output from its recombinant antigen development program launched in 2025. By adding internally produced synthetic antigens to its long-established native antigen capabilities, the company aims to strengthen supply-chain security, cost control, and technical flexibility for quality assessment materials used in proficiency testing and clinical lab quality management, particularly for enduring SARS-CoV-2 testing needs, where related QAPs already represent a meaningful share of its C$5.6 million fiscal 2025 QAPs revenue.
The most recent analyst rating on (TSE:MBX) stock is a Hold with a C$0.21 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.
Microbix reported a challenging fiscal 2025, with full-year revenue falling 27% to $18.6 million and the company swinging from net income of $3.5 million in the prior year to a net loss of $2.2 million. The downturn was driven by the absence of prior-year licensing revenue from its Kinlytic asset, weaker antigen sales into China amid fewer respiratory infections, and the cancellation of test-development programs by a major QAPs client, all of which compressed gross margins from 61% to 53% and increased pressure from operating expenses. Fourth-quarter revenue declined 41% to $3.7 million, led by a 55% drop in antigen sales as Chinese demand softened and shipments to a large European customer were delayed, resulting in a quarterly net loss of $1.5 million and a sharp margin deterioration. Despite these setbacks, the company highlighted ongoing investments in manufacturing efficiency, new product development, and expanded client relationships, and it ended the year with a strong liquidity position, including $12.1 million in cash and a high current ratio, positioning it to pursue new products and customers to rebuild revenue above breakeven levels.
The most recent analyst rating on (TSE:MBX) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.
Microbix Biosystems Inc. has announced the upcoming release of its financial results for the fourth quarter of fiscal 2025, scheduled for December 18, 2025. The company will host a webinar to discuss these results, featuring its CEO, CFO, and COO. This announcement highlights Microbix’s commitment to transparency and engagement with its stakeholders, potentially impacting its market positioning and investor relations.
The most recent analyst rating on (TSE:MBX) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.
Microbix Biosystems Inc. has launched new QAPs™ quality assessment products and QUANTDx™ reference materials to support testing for the H3N2 strain of Influenza A, which is experiencing an antigenic drift, affecting immunity and test accuracy. The company’s new products are designed to ensure reliable detection of H3N2 variants, providing stability and accuracy for laboratories and test developers, thus supporting effective public health responses and improving healthcare outcomes globally.
The most recent analyst rating on (TSE:MBX) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.
Microbix Biosystems Inc. and Seegene Mexico have partnered to enhance the accuracy of HPV tests across Mexico by utilizing Microbix’s quality assessment products with Seegene’s molecular multiplex assays. This collaboration aims to improve public health efforts for cervical cancer surveillance and ensure high international quality standards in clinical labs, with potential expansion into other infectious disease diagnostics.
The most recent analyst rating on (TSE:MBX) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.
Microbix Biosystems Inc. has partnered with SEKISUI Diagnostics to support the U.S. commercialization of a molecular point-of-care assay for COVID/Flu diagnosis using the Metrix platform from Aptitude Medical Systems. Microbix will provide its REDxFLOQ QAPs to support SEKISUI’s distribution of the test, which is available under an Emergency-Use Authorization from the U.S. FDA. This collaboration aims to enhance the accuracy and reliability of the test by providing operator-training materials and ensuring compliance with quality systems, thereby strengthening Microbix’s position in the diagnostics industry.
The most recent analyst rating on (TSE:MBX) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.
Microbix Biosystems Inc. announced it is addressing a cybersecurity incident involving a ransomware attack that resulted in data theft but did not impact operations. The company has been enhancing its cybersecurity measures since 2022, including adopting Center for Internet Security frameworks, conducting regular employee training, and implementing real-time threat monitoring. Microbix’s policy is to not pay ransoms, aiming to discourage cybercrime. The incident underscores the importance of robust cybersecurity in the life sciences industry, and Microbix continues to improve its IT security to adapt to increasing cyber threats.
The most recent analyst rating on (TSE:MBX) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.